Having finished reading the fascinating book, “Thou shalt Innovate: How Israeli Ingenuity Repairs the World”, by Avi Jorisch, a single thought kept repeating on a loop in my brain. What is so different about Israel? After all, Israel was founded only 64 years ago on almost barren terrain with hardly any natural resources, little water and with more than half […]
Judgement Date: Aug 14, 2019 Shogun Organics Limited (the plaintiff), has filed the present suit seeking a permanent injunction restraining infringement of its Patent IN-236630 (IN‘630) against Defendants (Solex Chemicals Pvt. Ltd, Director of the Solex, Orachem Pvt. Ltd (Trading partner of Solex), Manaksia Ltd, and Endura SPA. The IN’630 patent relates to a “Process for manufacturing D-trans Allethrin”. Allethrin […]
On Aug. 20, 2019, High Court of Delhi Passed order that “Patent infringement actions are maintainable only in respect of granted and live patents.” Plaintiff: Novartis AG & ANR. . Defendant: Natco Pharma Ltd. The suit concerns the Plaintiff’s patent number IN 276026 titled ‘Novel Pyrimidine Compounds and Compositions as Protein Kinase Inhibitors” relating Ceritinib drug for treating non-small cell […]
A division bench (judgement dated 27th Nov 2015) of the Delhi High Court sided with Roche against Indian firm Cipla, upholding the Swiss drug maker’s patent claims on key lung cancer drug erlotinib hydrochloride, branded Tarceva. Cipla’s Erlocip was launched in 2008 it cost around Rs 1,600 per tablet, as compared to Roche’s Tarceva which cost around Rs 4,800 per tablet. […]
On June 20, 2016, the Supreme Court of United States issued its first decision addressing IPR proceedings—Cuozzo Speed Technologies v. Lee. The court’s decision upheld the claim construction standard (“broadest reasonable interpretation” BRI rather than the “plain and ordinary meaning” standard applicable in courts) applied in IPR proceedings and confirmed that appeals may only be taken from the board’s final written decisions […]
India has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca’s key antidiabetes compound Saxagliptin sought by Hyderabad-based Lee Pharma. The Controller of Patents office rejected the application on the grounds that substitutes to the drug are readily available in the market and Lee Pharma’s claim that requirements of public with respect to the patented invention are not being […]
New Molecular Entity Drug Name Active Ingredient Date FDA-approved use on approval date Aristada aripiprazole lauroxil 10/6/2015 To treat adults with schizophrenia Tresiba insulin degludec injection 9/25/2015 To improve blood sugar (glucose) control in adults with diabetes mellitus Lonsurf trifluridine and tipiracil 9/22/2015 To treat patients with an advanced form of colorectal cancer who are no longer responding to other […]
Swiss pharmaceutical firm Helsinn Healthcare SA on October 13th 2015 said it has settled patent litigations relating to its anti-nausea injection Aloxi with Dr. Reddy’s Laboratories Ltd. The settlement will allow Dr. Reddy’s to market the generic version of Aloxi in the US on 30 September 2018 or earlier under certain circumstances, Helsinn said in a statement.The terms of the settlement […]
Gene Patents struck down by Australia’s High Court saying that allowing patents of genes were wrong, and they do not constitute a patentable invention. The judges unanimously agreed on the outcome that the key part of a gene is not its physical structure but rather the information stored in it, which is not an invention. They also said that if […]
Indian Patent Office has denied Germany’s Boehringer Ingelheim a patent on its key HIV drug, Nevirapine, for a version sold as Viramune XR (extended release). VIRAMUNE XR was approved in US on Mar 25, 2011 (100 mg and 400 mg, TABLET) and OB listed US patent will expire on Mar. 12, 2015. The application on the Nevirapine extended release formulation […]